Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Jul 07, 2023
TickeronGET DAILY SIGNALS
AI Trading Bots Generate Impressive strong performance on TLRY: Deep Trend Analysis v.2 (TA) Signals Bullish Momentum

AI Trading Bots Generate Impressive strong performance on TLRY: Deep Trend Analysis v.2 (TA) Signals Bullish Momentum

The Swing trader: Deep Trend Analysis v.2 (TA) bot, which has recently showcased its prowess by generating an impressive +strong performance while trading TLRY over the course of the previous week. In this article, we will delve into the significance of this performance and analyze the latest earnings report to gain insights into the future growth prospects of this stock.

Bullish Momentum and AI Trading:

The AI trading robot, accessible through Swing trader: Deep Trend Analysis v.2 (TA) demonstrated a noteworthy achievement by capitalizing on TLRY's upward movement. The stock has been moving higher for three consecutive days, which is generally viewed as a bullish sign in technical analysis. This positive trend caught the attention of the AI bot, prompting it to execute successful trades and achieve a substantial gain.

Analyzing Historical Data:

To gauge the potential for future growth, it is essential to consider historical data and evaluate similar scenarios. Examining situations where TLRY advanced for three consecutive days, we find that in 179 out of 220 cases, the price continued to rise further within the following month. This analysis reveals that the odds of a continued upward trend are remarkably high at 81%. Therefore, investors should keep a close watch on TLRY as it holds promising prospects for further gains.

Earnings Report Highlights:

Apart from technical indicators, fundamental factors such as earnings reports play a significant role in assessing a company's financial health and potential stock performance. The last earnings report on April 10 showed earnings per share of -3 cents, surpassing the estimated -5 cents. This positive surprise indicates that TLRY performed better than expected, reflecting the company's ability to effectively manage its operations.

Market Capitalization and Shares Outstanding:

TLRY currently has 14.23 million shares outstanding, which is a critical factor in determining the stock's value. With this number in mind, the current market capitalization of TLRY stands at an impressive 1.12 billion dollars. Market capitalization is a key metric used by investors to assess the size and worth of a company. TLRY's market cap demonstrates its significant presence in the market and reinforces its potential for growth.

Summary:

The recent success of the AI trading bot, Swing trader: Deep Trend Analysis v.2 (TA) in generating a +strong performance while trading TLRY highlights the growing influence of AI in the financial industry. TLRY's three-day upward trend coupled with historical data analysis indicates a high probability of continued growth. Additionally, TLRY's earnings report showed promising results, surpassing market expectations. With a market capitalization of 1.12 billion dollars, TLRY remains an attractive option for investors seeking potential opportunities in the market.

Related Ticker: TLRY

Contributor

Dem Sem's AvatarDem Sem|Expert

TLRY's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for TLRY turned positive on November 04, 2026. Looking at past instances where TLRY's MACD turned positive, the stock continued to rise in 37 of 41 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TLRY's RSI Indicator exited the oversold zone, 40 of 50 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.

Following a +16.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLRY advanced for three days, in 166 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 46 cases where TLRY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TLRY as a result. In 71 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for TLRY entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.254) is normal, around the industry mean (6.379). P/E Ratio (-2.679) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.481) is also within normal values, averaging (183.387).

The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. TLRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Aurora Cannabis (NASDAQ:ACB), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.46B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 0%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 10%. XERS experienced the highest price growth at 53%, while AKAN experienced the biggest fall at -32%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 10%. For the same stocks of the Industry, the average monthly volume growth was 21% and the average quarterly volume growth was 16%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 55
Price Growth Rating: 61
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 3 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a holding company, whose subsidiaries engages in research, cultivation, processing and distribution of medical cannabis

Industry PharmaceuticalsGeneric

Industry
Biotechnology
Address
265 Talbot Street West
Phone
+1 844 845-7291
Employees
3595
Web
https://www.tilray.com
Interact to see
Advertisement
AtlasClear Holdings (ATCH) shares fell roughly 25.5% over the last 30 days, declining from $0.1881 on October 2 to $0.1401 on October 30. The pullback extended a longer downtrend that has kept the stock trading well below the $1.00 NYSE American minimum, keeping continued listing-compliance risk in focus.
The central target of $1,620 is the arithmetic mean of verified, current analyst price targets, rounded to a clean level; it is not a single firm's forecast or a guarantee. At a recent price of about $690 , reaching $1,620 would require a gain of roughly 135% , a very large move by any standard.
NVDA fell -2.10% to $216.66 during regular trading, down from a prior close of $221.30. Primary catalyst: hotter-than-expected September CPI data reignited Fed rate-hike fears, raising borrowing costs for AI infrastructure buildouts.
XRPN fell -9.70% in early regular-session trading on Tuesday, sliding from Monday's $10.41 close to $9.40. The decline follows a November 9 SEC prospectus disclosing a committed equity facility with Cantor to sell up to 5.2 million new Class A shares at 97% of the volume-weighted average price, implying up to roughly 16.7% potential dilution.
The $1.14 central target is not an analyst consensus; it is the all-cash merger consideration in GoPro, Inc. (GPRO) 's pending deal with Starman Optical, agreed in September 2026. With the stock trading near $0.88, reaching $1.14 would require a move of roughly 29.5%.